Women's Health

Roundup: US FDA clears Medical IP’s AI body composition analysis software and other submissions



Medical IP gets US FDA approval for AI body composition analysis software

South Korean medical imaging company Medical IP has obtained 510(k) clearance from the U.S. Food and Drug Administration for its AI-powered body composition analysis software.

According to the company, DeepCatch is the first FDA-approved AI software that automatically analyzes body components, such as skin, bones, muscles, visceral fat, subcutaneous fat, internal organs and body tissue. central nervous system, by whole body scanner. It provides reports with 3D visual and quantitative information.

With this FDA clearance, Medical IP will accelerate its global expansion plan.

Augnito launches ambient technology for clinical documentation

Indian health technology company Augnito has introduced ambient technology for clinical documentation.

Based on a press release, the technology allows physicians to document patient encounters and generate documentation and data. It transcribes the consultation between the doctor and the patient in real time with “absolute” precision, then it generates a structured SOAP note.

It can transcribe other types of conversations, including major complaints, medical histories, diagnoses, recommended care plans, prescriptions, and follow-up appointment details, among others. Augnito’s AI can understand all English accents with 99% accuracy and transcribe multilingual conversations in over 10 Indian languages ​​and Arabic. It also addresses more than 50 medical specialties.

The technology can also automate administrative tasks, such as creating charts, entering data, and generating reports, which doctors still have to do despite using an EMR system.

CXR solution powered by Lunit eligible for reimbursement in Japan

Fujifilm’s AI solution for analyzing chest X-rays, CXR-AID, which is powered by the Lunit INSIGHT CXR, has become eligible for reimbursement by health insurance in Japan, Lunit announced.

It is provided under the Department of Health, Labor and Welfare Class 3 reimbursement category for hospitals using AI imaging diagnostic software. CXR-AID is also one of the 17 medical AI software options recommended in the Japan Radiological Society’s new guideline for implementing AI solutions in hospitals.

According to a press release, the inclusion of reimbursement “significantly boosts” the expansion of Lunit and Fujifilm in the Japanese market, and creates new growth prospects in the field of AI image diagnosis.



Back to top button